Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPAR-ICAS pemafibrate trial in symptomatic intracranial artery stenosis
jRCTs031260001Recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of pemafibrate in Cerebral atherosclerotic stenosis (ICAD) and hypertriglyceridemia (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: Progression of intracranial arterial stenosis on CTA at 12 months. Started May 2026; status: recruiting.
02
Drugs
pemafibrate
03
Conditions
Cerebral atherosclerotic stenosis (ICAD)hypertriglyceridemia
Beyond the preview
Go deeper on jRCTs031260001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260001.